{"id":"xzp-3287-fulvestrant","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reaction"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to the estrogen receptor, promoting its degradation and reducing estrogen signaling. XZP-3287's mechanism is unknown.","oneSentence":"XZP-3287+Fulvestrant is a combination of XZP-3287 and Fulvestrant, which works by inhibiting the estrogen receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:14.240Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced breast cancer"}]},"trialDetails":[{"nctId":"NCT04539496","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","startDate":"2018-05-22","conditions":"Metastasis Solid Tumors, Advanced Breast Cancer","enrollment":402},{"nctId":"NCT05077449","phase":"PHASE3","title":"A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2021-11-16","conditions":"Advanced Breast Cancer","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"XZP-3287+Fulvestrant","genericName":"XZP-3287+Fulvestrant","companyName":"Xuanzhu Biopharmaceutical Co., Ltd.","companyId":"xuanzhu-biopharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XZP-3287+Fulvestrant is a combination of XZP-3287 and Fulvestrant, which works by inhibiting the estrogen receptor. Used for Advanced breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}